Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

ClinicalTrials.gov ID

NCT07797231

Lead Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

930Estimated

Last Update Posted

Sep 3, 2026Actual

Start Date

Sep 2026Estimated

Primary Completion Date

Sep 2028Estimated

Completion Date

Oct 2029Estimated

Official Title

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial With an Open-Label Extension to Evaluate the Efficacy and Safety of TQA3605 Tablets in Chronic Hepatitis B Virus-Infected Patients With Low-Level Viremia or Suboptimal Response After at Least 12 Months of NAs Therapy

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III study with an open-label extension. The purpose is to evaluate efficacy and safety in adult patients with chronic hepatitis B virus infection who have received at least 12 months of NAs therapy, to demonstrate that TQA3605 Tablets combined with oral nucleos(t)ide analogues can improve efficacy with satisfactory safety profile compared with oral nucleos(t)ide analogues alone in this population. Approximately 930 adult patients with chronic hepatitis B virus infection who have received at least 12 months of NAs therapy are planned to be enrolled in this study.

• Chronic Hepatitis B

• TQA3605 tablets Placebo
• TQA3605 tablets
• Entecavir dispersible tablets
• Tenofovir Disoproxil Fumarate Tablets
• Tenofovir Alafenamide Fumarate Tablets
• Tenofovir Amibufenamide Tablets

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Male or female participants aged 18-65 years (inclusive) at screening.
• Able to communicate effectively with the investigator, understand and comply with all requirements of this study, and understand and sign the informed consent form.
• Have received continuous treatment with nucleos(t)ide analogues (entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate or tenofovir amibufenamide) or NAs combination therapy for ≥ 12 months at screening, with a stable single regimen for ≥ 6 months (medication adherence > 90% in the past 12 months, with no treatment interruption exceeding 15 consecutive days).
• Etiological evidence is available at screening to confirm chronic HBV infection of more than 1 year (HBsAg positive and/or HBV DNA positive for at least 1 year).
• HBV DNA > 50 IU/mL detected by a local medical institution within 30 days prior to screening, which is reconfirmed as HBV DNA > 50 IU/mL by the central laboratory during the screening period.
• HBeAg positive as confirmed by the central laboratory at screening.
• Male trial participants with fertile female partners or female participants of childbearing potential are willing to use effective contraception from screening until 3 months after study discontinuation.

Exclusion Criteria:

• Pregnant women (positive pregnancy test) or breastfeeding women.
• Co-infection with other viruses such as HAV, HCV, HDV, HEV, HIV, or syphilis (participants with positive syphilis antibody who require treatment as judged by the investigator; Participants with positive HCV antibody and negative HCV RNA may not be excluded).
• History of liver cirrhosis; or liver histopathology obtained within 1 year prior to screening indicating Metavir ≥ S3, Scheuer ≥ S3 or Ishak ≥ S4; or FibroScan result ≥ 9.0 kPa within 6 months prior to screening; or previous endoscopy revealing esophageal and gastric varices; or suspected liver cirrhosis identified on abdominal ultrasonography at screening, such as ascites, hepatic encephalopathy, and bleeding from esophageal and gastric varices.
• History of hepatocellular carcinoma (HCC) or suspected HCC at or prior to screening (e.g., suspicious lesions on imaging, or AFP ≥ 50 ng/mL).
• History of malignant tumor within 5 years prior to screening, except for certain malignancies that are completely curable after surgical resection (e.g., basal cell carcinoma of the skin). Trial participants under evaluation for active or suspected malignant tumor at screening.
• Trial participants with other chronic liver diseases, including but not limited to autoimmune liver disease, alcoholic liver disease, Wilson's disease, metabolic dysfunction-associated steatohepatitis (MASH).
• Clinically significant abnormal laboratory parameters at screening (abnormal values may be retested once): Hematology: white blood cell count less than 3 ×10⁹/L, neutrophil count less than 1.5 ×10⁹/L, platelet count less than 100 ×10⁹/L, or hemoglobin less than 100 g/L. Biochemistry: estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI formula ≤ 60 mL/min/1.73 m²; ALT or AST greater than 3 × ULN; total bilirubin greater than 2 × ULN; albumin less than 30 g/L; total cholesterol ≥ 7.75 mmol/L; triglycerides ≥ 3.42 mmol/L; serum uric acid greater than 420 μmol/L. Coagulation: international normalized ratio (INR) greater than 1.5.4) Antinuclear antibody (ANA) greater than 1:100 (indirect immunofluorescence, IIF). If ANA = 1:100, the investigator shall assess whether there is relevant medical history or symptoms of connective tissue disease or autoimmune disease.
• Electrocardiogram showing clinically significant abnormalities at screening rendering the participant unsuitable for trial participation as judged by the investigator.
• Autoimmune diseases including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, sarcoidosis, psoriasis, autoimmune uveitis.
• Significant systemic or severe diseases other than liver disease, including recent (≤ 6 months prior to screening) congestive heart failure (New York Heart Association (NYHA) Functional Classification III-IV), unstable coronary artery disease, arterial revascularization, respiratory diseases, renal insufficiency, stroke, transient ischemic attack, organ transplantation, psychiatric disorders. Uncontrolled systemic diseases: poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg); poorly controlled diabetes (fasting plasma glucose (FPG) greater than 10 mmol/L).
• Major trauma or major surgery within 3 months prior to screening, or planned surgery during the study period.
• Received any systemic anti-tumor therapy (including radiotherapy), immunosuppressive therapy (including biological immunosuppressants), or immunomodulatory therapy within 6 months prior to screening (including oral non-biological immunomodulatory agents such as methotrexate greater than 25 mg/week, azathioprine greater than 3 mg/kg/day, or 6-mercaptopurine greater than 1.5 mg/kg/day).
• Received high-dose systemic corticosteroids within 3 months prior to screening, defined as prednisone ≥ 40 mg/day for more than 7 consecutive days or prednisone ≥ 20 mg/day for more than 14 consecutive days.
• History of drug dependence or substance abuse.
• History of excessive alcohol consumption. Excessive alcohol consumption is defined as weekly ethanol intake exceeding 210 g for males and 140 g for females over the past 12 months. Ethanol intake (g) = Volume consumed (mL) × Alcohol by volume (%) × 0.8.
• History of allergy to the investigational product or its excipients.
• Previous participation in clinical trials of hepatitis B core protein allosteric modulators (CpAMs).
• Participated in other clinical trials of investigational drugs or medical devices and received study intervention within 3 months prior to screening.
• Participants deemed inappropriate for enrollment by the investigator.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY

44271370@qq.com15956927046

wuhm2000@sina.com13693259096

ddcatih@sina.com13661195941

xubin1016@126.com13716830822

qingmao@tmmu.edu.cn13594180020

13896208811@163.com13896208811

gaohb605@163.com13159438353

Xuhongzhi07@163.com13606000360

Icheneye@163.com13993173526

925944468@qq.com18993531188

splyc@126.com13425661266

pliang@mail.sysu.edu.cn13533978874

huguoxin8228@sina.com13823608228

13926931110@163.com13926931110

13978009767@139.com13978009767

penghonggz@126.com13885035037

823357828@qq.com18786912014

13876371288@163.com13876371288

594957495@qq.com13831653827

413699442@qq.com13313019790

ganranke@126.com13804535357

lm19780816@126.com13936368393

mdjzengxiqiu@126.com18645753000

iamcfj@qq.com16637232481

695284544@qq.com15839335025

lgm177@sina.com13603715881

ananli1984@126.com18595825852

13508610186@163.com181071617200

jiangyongfang@csu.edu.cn13875858624

hncspzt@163.com13873488377

liyz2008@163.com15096257715

doctorluling@163.com15847387386

Lilid1973@sina.com13512501015

lijier@sina.com15863787910

zhuchw@126.com13606202525

wuxiaoping2823@aliyun.com13330122823

sunshuilin2280@126.com13803500270

2813794970@qq.com13578670535

759844822@qq.com13604310429

junqiniu@aliyun.com13756661205

15909862690@139.com18004266010

wy@mail.sy.ln.cn18502460852

yding0903@sina.com13332434847

13997384855@163.com13997384855

fleming7798@126.com18609175079

Heyingli2000@163.com18991232863

dang212@123.com13992896471

18765870708@126.com18765870708

13346253998@163.com13346253998

xinyongning@163.com18661678200

Chenjh328@163.com13864629070

18916510601@163.com18916510601

xiongwujun@126.com13916617586

732791146@qq.com18918157268

chenxiaohua2000@163.com18930172758

zyw5680@126.com15035899899

fengjing791120@126.com13753104039

clj881@126.com13453938813

673043401@qq.com13730803139

gscxb-11@163.com13881088112

3431281705@qq.com13778888362

wangfengmeitj@126.com15522242696

Xjykdluxiaobo@126.com159 9917 6213‬‬‬‬‬‬‬‬

429596667@qq.com13577093765

lslvjiaojian@163.com18957091505

qianyuns@163.com13645740222

zhujs@enzemed.com13806561595

YahoshongLiang@163.com13958805550

• A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

  NCT06150014

  Active, not recruitingInterventionalPhase 1Phase 2Updated Nov 14, 2024
• Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection

  NCT06644417

  CompletedInterventionalPhase 2Updated Jan 26, 2026
• A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B

  NCT06566248

  Unknown statusInterventionalPhase 2Updated Aug 22, 2024
• A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

  NCT06990776

  WithdrawnInterventionalPhase 2Updated Aug 3, 2025
• Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection

  NCT06706310

  Active, not recruitingInterventionalPhase 2Updated Sep 11, 2026
• A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B

  NCT06452693

  Not yet recruitingInterventionalPhase 1Phase 2Updated Jun 11, 2024